Gemcitabine and targeted therapy in metastatic breast cancer

Guangzhi Qu, Edith A. Perez

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Gemcitabine, a new cytotoxic nucleoside analog, has demonstrable single-agent antitumor activity in metastatic breast cancer. Recently, nearly 20 phase II clinical trials of gemcitabine alone or as part of combination therapy have confirmed its role in this disease. As a single agent, gemcitabine leads to response rates ranging from 16% to 37% in either first-line and/or refractory settings. Combined with platinum, taxanes, vinorelbine, and anthracyclines as doublets or triplets, response rates in the range of 50% to 80% have been reported in small phase II clinical trials. The relatively mild toxicity profile of gemcitabine makes it an attractive agent to evaluate in combination with targeted drugs such as trastuzumab, tyrosine kinase inhibitors, and angiogenesis inhibitors, among others. In this review we summarize current available data of gemcitabine in the management of metastatic breast cancer, and provide a perspective of gemcitabine in future clinical research for management of this disease.

Original languageEnglish (US)
Pages (from-to)44-52
Number of pages9
JournalSeminars in Oncology
Volume29
Issue number3 SUPPL. 11
StatePublished - 2002

Fingerprint

gemcitabine
Breast Neoplasms
Phase II Clinical Trials
Therapeutics
Taxoids
Angiogenesis Inhibitors
Anthracyclines
Disease Management
Platinum
Nucleosides
Antineoplastic Agents
Protein-Tyrosine Kinases

ASJC Scopus subject areas

  • Oncology

Cite this

Qu, G., & Perez, E. A. (2002). Gemcitabine and targeted therapy in metastatic breast cancer. Seminars in Oncology, 29(3 SUPPL. 11), 44-52.

Gemcitabine and targeted therapy in metastatic breast cancer. / Qu, Guangzhi; Perez, Edith A.

In: Seminars in Oncology, Vol. 29, No. 3 SUPPL. 11, 2002, p. 44-52.

Research output: Contribution to journalArticle

Qu, G & Perez, EA 2002, 'Gemcitabine and targeted therapy in metastatic breast cancer', Seminars in Oncology, vol. 29, no. 3 SUPPL. 11, pp. 44-52.
Qu, Guangzhi ; Perez, Edith A. / Gemcitabine and targeted therapy in metastatic breast cancer. In: Seminars in Oncology. 2002 ; Vol. 29, No. 3 SUPPL. 11. pp. 44-52.
@article{204834e2d7ff49aeab7e2b4f807863c2,
title = "Gemcitabine and targeted therapy in metastatic breast cancer",
abstract = "Gemcitabine, a new cytotoxic nucleoside analog, has demonstrable single-agent antitumor activity in metastatic breast cancer. Recently, nearly 20 phase II clinical trials of gemcitabine alone or as part of combination therapy have confirmed its role in this disease. As a single agent, gemcitabine leads to response rates ranging from 16{\%} to 37{\%} in either first-line and/or refractory settings. Combined with platinum, taxanes, vinorelbine, and anthracyclines as doublets or triplets, response rates in the range of 50{\%} to 80{\%} have been reported in small phase II clinical trials. The relatively mild toxicity profile of gemcitabine makes it an attractive agent to evaluate in combination with targeted drugs such as trastuzumab, tyrosine kinase inhibitors, and angiogenesis inhibitors, among others. In this review we summarize current available data of gemcitabine in the management of metastatic breast cancer, and provide a perspective of gemcitabine in future clinical research for management of this disease.",
author = "Guangzhi Qu and Perez, {Edith A.}",
year = "2002",
language = "English (US)",
volume = "29",
pages = "44--52",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 11",

}

TY - JOUR

T1 - Gemcitabine and targeted therapy in metastatic breast cancer

AU - Qu, Guangzhi

AU - Perez, Edith A.

PY - 2002

Y1 - 2002

N2 - Gemcitabine, a new cytotoxic nucleoside analog, has demonstrable single-agent antitumor activity in metastatic breast cancer. Recently, nearly 20 phase II clinical trials of gemcitabine alone or as part of combination therapy have confirmed its role in this disease. As a single agent, gemcitabine leads to response rates ranging from 16% to 37% in either first-line and/or refractory settings. Combined with platinum, taxanes, vinorelbine, and anthracyclines as doublets or triplets, response rates in the range of 50% to 80% have been reported in small phase II clinical trials. The relatively mild toxicity profile of gemcitabine makes it an attractive agent to evaluate in combination with targeted drugs such as trastuzumab, tyrosine kinase inhibitors, and angiogenesis inhibitors, among others. In this review we summarize current available data of gemcitabine in the management of metastatic breast cancer, and provide a perspective of gemcitabine in future clinical research for management of this disease.

AB - Gemcitabine, a new cytotoxic nucleoside analog, has demonstrable single-agent antitumor activity in metastatic breast cancer. Recently, nearly 20 phase II clinical trials of gemcitabine alone or as part of combination therapy have confirmed its role in this disease. As a single agent, gemcitabine leads to response rates ranging from 16% to 37% in either first-line and/or refractory settings. Combined with platinum, taxanes, vinorelbine, and anthracyclines as doublets or triplets, response rates in the range of 50% to 80% have been reported in small phase II clinical trials. The relatively mild toxicity profile of gemcitabine makes it an attractive agent to evaluate in combination with targeted drugs such as trastuzumab, tyrosine kinase inhibitors, and angiogenesis inhibitors, among others. In this review we summarize current available data of gemcitabine in the management of metastatic breast cancer, and provide a perspective of gemcitabine in future clinical research for management of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0036311866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036311866&partnerID=8YFLogxK

M3 - Article

C2 - 12138397

AN - SCOPUS:0036311866

VL - 29

SP - 44

EP - 52

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 11

ER -